MX9701183A - Procedimiento de preparacion del virus gripal, antigenos obtenidos y sus aplicaciones. - Google Patents

Procedimiento de preparacion del virus gripal, antigenos obtenidos y sus aplicaciones.

Info

Publication number
MX9701183A
MX9701183A MX9701183A MX9701183A MX9701183A MX 9701183 A MX9701183 A MX 9701183A MX 9701183 A MX9701183 A MX 9701183A MX 9701183 A MX9701183 A MX 9701183A MX 9701183 A MX9701183 A MX 9701183A
Authority
MX
Mexico
Prior art keywords
steps
preparing
applications
influenza virus
influenzal
Prior art date
Application number
MX9701183A
Other languages
English (en)
Inventor
Jean-Michel Violay
Guy Court
Catherine Gerdil
Herve Chalumeau
Patrick Verry
Original Assignee
Pasteur Merieux Serums Vacc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Merieux Serums Vacc filed Critical Pasteur Merieux Serums Vacc
Publication of MX9701183A publication Critical patent/MX9701183A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16163—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Procedimiento de preparacion de antígenos gripales purificados, a partir de un líquido que contiene el virus gripal, que comprende las etapas de concentracion de purificacion, de fragmentacion y eventualmente de inactivacion caracterizado porque: A. o bien la etapa de purificacion comprende varias etapas de ultracentrifugacion separadas por una etapa de filtracion, B. o bien la etapa de fragmentacion no ionico anfífilo seguido de una eliminacion de substancias indeseables por filtracion que retiene el conjunto de constituyentes virales, o bien se opera de acuerdo a estas dos etapas en cualquier orden.
MX9701183A 1994-08-16 1995-06-06 Procedimiento de preparacion del virus gripal, antigenos obtenidos y sus aplicaciones. MX9701183A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9410039A FR2723740B1 (fr) 1994-08-16 1994-08-16 Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
PCT/FR1995/000727 WO1996005294A1 (fr) 1994-08-16 1995-06-06 Procede de preparation du virus grippal, antigens obtenus et leurs applications

Publications (1)

Publication Number Publication Date
MX9701183A true MX9701183A (es) 1997-05-31

Family

ID=9466323

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701183A MX9701183A (es) 1994-08-16 1995-06-06 Procedimiento de preparacion del virus gripal, antigenos obtenidos y sus aplicaciones.

Country Status (10)

Country Link
US (1) US6048537A (es)
EP (1) EP0776362A1 (es)
JP (1) JPH10504033A (es)
AU (1) AU701024B2 (es)
CA (1) CA2197683C (es)
FR (1) FR2723740B1 (es)
MX (1) MX9701183A (es)
NZ (1) NZ288254A (es)
WO (1) WO1996005294A1 (es)
ZA (1) ZA956797B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19938767C2 (de) * 1999-08-16 2002-10-24 Tad Pharma Gmbh Spaltimpfstoffe
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
EP1103610A1 (en) * 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
US6951752B2 (en) 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
KR100473070B1 (ko) * 2002-08-31 2005-03-10 박승국 시각적 유도장치를 이용한 외국어 학습 및 교습 시스템
CA2503774C (en) * 2003-06-20 2007-09-25 Microbix Biosystems Inc. Improvements in virus production
US20080254067A1 (en) * 2004-05-20 2008-10-16 Id Biomedical Corporation Process for the Production of an Influenza Vaccine
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
BRPI0618254A2 (pt) * 2005-11-04 2011-08-23 Novartis Vaccines & Diagnostic emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido
CA2642485A1 (en) * 2006-02-23 2007-08-30 Leonard Moran Improved methods of producing avian eggs and birds of specified germ-free status
JP2010524508A (ja) * 2007-04-27 2010-07-22 ダウ グローバル テクノロジーズ インコーポレイティド 可溶性組換え二十面体ウイルス様粒子の生産及びインビボ組織化の改善
JP5352578B2 (ja) * 2007-05-04 2013-11-27 バクスター・インターナショナル・インコーポレイテッド ウイルスの増殖のための二段階温度プロフィール
US8497112B2 (en) * 2007-08-28 2013-07-30 Baxter International Inc. Method for producing viral vaccines
TW200936758A (en) * 2007-11-02 2009-09-01 Intervet Int Bv Orthomyxoviridae propagation
TWI444384B (zh) * 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
KR101695800B1 (ko) 2008-03-05 2017-02-22 사노피 파스퇴르 항원보강제 함유 백신 조성물의 안정화 방법
ES2535101T3 (es) 2008-03-18 2015-05-05 Novartis Ag Mejoras en la preparación de antígenos en vacuna de virus de la gripe
EP2393922A1 (en) 2009-02-06 2011-12-14 GlaxoSmithKline Biologicals S.A. Purification of virus or viral antigens by density gradient ultracentrifugation
JP5823379B2 (ja) * 2009-05-29 2015-11-25 ノバルティス アーゲー インフルエンザウイルスヘマグルチニンについてのアッセイ
US9107859B2 (en) 2009-09-10 2015-08-18 Merial, Inc. Vaccine formulations comprising saponin-containing adjuvants
JP2013523175A (ja) 2010-04-14 2013-06-17 イーエムディー・ミリポア・コーポレーション 高力価、高純度のウイルスストックの作製方法及びその使用方法
CA2844927C (en) 2011-08-12 2017-10-31 Merial Limited Vacuum-assisted preservation of biological products, in particular of vaccines
FR3025107B1 (fr) 2014-08-29 2018-10-05 Calixar Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations
TWI745278B (zh) 2014-10-10 2021-11-11 以色列商艾畢克生物實驗有限公司 發泡性降低之疫苗組合物
DK3471760T3 (da) 2016-06-17 2025-01-27 Boehringer Ingelheim Vetmedica Gmbh Hidtil ukendte immunogene formuleringer, der omfatter lineære eller forgrenede polyacrylsyrepolymeradjuvanser
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
US4000257A (en) * 1975-12-22 1976-12-28 American Cyanamid Company Process for the purification of influenza virus vaccine
US4057626A (en) * 1976-10-08 1977-11-08 Richardson-Merrell Inc. Process for detoxifying influenza B virus
FR2475572A1 (fr) * 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
DE3014189A1 (de) * 1980-04-14 1981-10-15 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren
FR2483779A1 (fr) * 1980-06-05 1981-12-11 Synthelabo Procede pour isoler des antigenes glycoproteiques viraux et son application a la preparation de vaccins
US4327182A (en) * 1981-01-22 1982-04-27 Connaught Laboratories Incorporated Purification of influenza sub-unit vaccine
FR2671974A1 (fr) * 1991-01-24 1992-07-31 Pasteur Merieux Serums Vacc Composition vaccinale contre la grippe, a effet synergique, contenant comme additif du core de virus grippal.

Also Published As

Publication number Publication date
CA2197683C (en) 2008-12-30
JPH10504033A (ja) 1998-04-14
AU701024B2 (en) 1999-01-21
US6048537A (en) 2000-04-11
FR2723740A1 (fr) 1996-02-23
EP0776362A1 (fr) 1997-06-04
ZA956797B (en) 1997-02-17
CA2197683A1 (en) 1996-02-22
WO1996005294A1 (fr) 1996-02-22
FR2723740B1 (fr) 1996-11-08
AU2741295A (en) 1996-03-07
NZ288254A (en) 1999-01-28

Similar Documents

Publication Publication Date Title
MX9701183A (es) Procedimiento de preparacion del virus gripal, antigenos obtenidos y sus aplicaciones.
AU580402B2 (en) Method of inactivating viruses involving adsorption on solid phase
KR860008276A (ko) 단백질이 생성된 배양기로 부터 그것을 추출, 정제하는 방법
TR199901840T2 (xx) DNA'nın cross-flow-filtrasyonu ile temizlenmesi.
EP0630280A4 (en) METHOD AND DEVICE FOR REMOVING DNA, VIRUSES AND ENDOTOXINS.
ATE189697T1 (de) Die hocheffiziente herstellung und isolierung von viruspartikeln
ATE324436T1 (de) Verfahren zur reinigung von menschlichen, dem papillomavirus ähnlichen partikeln.
FI99192B (fi) Menetelmä virusten inaktivoimiseksi veressä ja verituotteissa
DE60132094D1 (de) Verfahren zur Herstellung von gereinigten Partikeln
DE69835294D1 (de) Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus-ähnlichen tielchen (vlps)
ATE278785T1 (de) Neues verfahren zur gewinnung und reinigung von fusionsproteinen
MX9304736A (es) Sistema y metodo para remover hidrocarburos a partir de mezclas gaseosas.
EP0884383A4 (en) METHOD FOR CLEANING AND REMOVING VIRUSES.
EP0932163A3 (en) Methods of removing radioactively labeled biological molecules from liquid radioactive waste
ATE283277T1 (de) Verfahren zur entfernung von viren aus proteinlösungen mittels nanofiltration
FR2459479B1 (fr) Procede de separation d'une substance proteinique a partir d'une solution la contenant par filtration d'affinite et application dudit procede aux dosages enzymatiques
EA199800685A1 (ru) Разделение компонентов плазмы крови с помощью фильтрующих средств на основе целлюлозы
DE59814369D1 (de) Filtrationsverfahren zur trennung von viren
DE69833256D1 (de) Methode zur entfernung von endotoxinen aus impstoffen
DE69940338D1 (de) Vereinfachte methode zur entfernung von freiem protein während der herstellung von protein-polysaccharid-konjugaten und impfstoffen unter verwendung von medien mit limitierter durchlässigkeit
AU6329099A (en) Method for purifying or isolating viral nucleic acids
CA2074824A1 (en) Process for depleting viruses in solutions and for determining the depletion rate of the viruses
ATE179428T1 (de) Verfahren zur herstellung von hepatitis antigenen und impfstoffen
AU640841B2 (en) Process for the purification of white phosphorus
ATE190492T1 (de) Verwendung von gift aus hautflüglern (hymenopteren) zur herstellung eines medikamentes zur behandlung von infektionen durch dna-viren